


VOYAGER PAD

#ACC20/#WCCardio



AMERICAN
COLLEGE of
CARDIOLOGY

Trial Description: Patients with lower extremity peripheral arterial disease undergoing revascularization were randomized to rivaroxaban 2.5 mg twice daily/aspirin vs. placebo/aspirin.



RESULTS

- Primary outcome, cardiovascular death, acute limb ischemia, major amputation, myocardial infarction, or stroke: 17.3% of the rivaroxaban/aspirin group vs. 19.9% of the placebo/aspirin group (p = 0.0085)
- Acute limb ischemia: 5.2% of the rivaroxaban/aspirin group vs. 7.8% of the placebo/aspirin group (p < 0.05)
- ISTH major bleeding: 5.9% of the rivaroxaban/aspirin group vs. 4.1% of the placebo/aspirin group (p = 0.0068)

CONCLUSIONS

- Among patients with lower extremity peripheral arterial disease undergoing revascularization, rivaroxaban/aspirin was associated with a reduction in major adverse limb and cardiovascular events compared with placebo/aspirin

Bonaca MP, et al. N Engl J Med 2020;Mar 28:[Epub]